Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives Consensus Recommendation of “Buy” from Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has received an average recommendation of “Buy” from the eight ratings firms that are presently covering the firm, Marketbeat.com reports. Seven analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $59.20.

Several research analysts have weighed in on the company. Canaccord Genuity Group lowered their target price on Arcturus Therapeutics from $74.00 to $68.00 and set a “buy” rating on the stock in a research note on Monday, March 10th. BTIG Research set a $48.00 price objective on shares of Arcturus Therapeutics and gave the stock a “buy” rating in a research report on Monday, March 10th. HC Wainwright restated a “buy” rating and issued a $60.00 target price on shares of Arcturus Therapeutics in a research note on Thursday, April 10th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Friday, March 7th. Finally, Wells Fargo & Company reduced their price objective on shares of Arcturus Therapeutics from $58.00 to $50.00 and set an “overweight” rating for the company in a research report on Friday, March 7th.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $12.82 on Tuesday. The firm’s fifty day simple moving average is $12.68 and its 200-day simple moving average is $15.96. Arcturus Therapeutics has a 12 month low of $8.04 and a 12 month high of $45.00. The stock has a market capitalization of $347.68 million, a price-to-earnings ratio of -5.77 and a beta of 3.41.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Thursday, March 6th. The biotechnology company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.78). Arcturus Therapeutics had a negative net margin of 36.39% and a negative return on equity of 22.39%. The business had revenue of $22.77 million during the quarter, compared to analysts’ expectations of $44.64 million. Analysts anticipate that Arcturus Therapeutics will post -2.22 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Byrne Asset Management LLC increased its stake in Arcturus Therapeutics by 89.8% in the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 1,365 shares in the last quarter. Virtus ETF Advisers LLC raised its stake in shares of Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company’s stock worth $69,000 after buying an additional 1,132 shares during the last quarter. KLP Kapitalforvaltning AS purchased a new stake in shares of Arcturus Therapeutics in the 4th quarter worth about $71,000. GAMMA Investing LLC grew its stake in Arcturus Therapeutics by 3,482.9% in the 1st quarter. GAMMA Investing LLC now owns 5,231 shares of the biotechnology company’s stock valued at $550,000 after acquiring an additional 5,085 shares during the last quarter. Finally, National Bank of Canada FI increased its holdings in Arcturus Therapeutics by 639.6% during the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company’s stock valued at $94,000 after acquiring an additional 4,784 shares in the last quarter. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.